Shengnan Yu

1095 Jiefang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Correction: DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis.

Correction: DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis.

Journal: Journal of hematology & oncology
Published: December 13, 2022

NRF2-Driven KEAP1 Transcription in Human Lung Cancer.

NRF2-Driven KEAP1 Transcription in Human Lung Cancer.

Journal: Molecular cancer research : MCR
Published: January 31, 2020

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer.

CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer.

Journal: Frontiers in oncology
Published: August 30, 2019

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.

Journal: Molecular cancer
Published: August 17, 2019

Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis.

Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis.

Journal: BioMed research international
Published: July 10, 2019

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.

Journal: Journal of experimental & clinical cancer research : CR
Published: May 04, 2019

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.

Journal: Molecular cancer
Published: May 01, 2019

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.

Journal: Journal of hematology & oncology
Published: January 21, 2019

Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA.

Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA.

Journal: Cancer management and research
Published: October 16, 2018

The role of neoantigen in immune checkpoint blockade therapy.

The role of neoantigen in immune checkpoint blockade therapy.

Journal: Experimental hematology & oncology
Published: September 20, 2018

MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer.

MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: July 27, 2018

Gut microbiome modulates efficacy of immune checkpoint inhibitors.

Gut microbiome modulates efficacy of immune checkpoint inhibitors.

Journal: Journal of hematology & oncology
Published: January 23, 2018
Showing 1-12 of 21

Last Updated: 09/26/2026